A Study of Camrelizumab As Consolidation Therapy After Radical Concurrent Chemoradiotherapy In Locally Advanced ESCC

Sponsor
Hebei Medical University Fourth Hospital
Study ID
NCT04286958
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Camrelizumab — DRUG
    Camrelizumab: 200 mg was given intravenously over a period of 30 minutes (no less than 20 minutes and no longer than 60 minutes)

Study Details

The purpose of this study is to assess efficacy and safety of patients who receive camrelizumab as consolidation therapy after radical concurrent chemoradiotherapy in locally advanced ESCC.

Key Dates

Start date
Apr 22, 2020
Status verified
Dec 2021
Primary completion
Dec 22, 2022
Completion
Mar 1, 2023

Study Design

Enrollment
40 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Camrelizumab
    All patients who had received radical concurrent chemoradiotherapy were treated with camrelizumab.

Primary Outcome Measure

Progression free survival (PFS) [ Time Frame: evaluated in 24 months since the treatment began ]

Central Contacts

Related Studies